RxDoctor Payments Data

Cynthia Argo

Family · Paris, TNNPI 1275536682

Payments from drug & device makers

$1,984in general payments, 2019–2025

Across 96 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$292
  • AstraZeneca$247
  • Welch Allyn$237
  • Lilly USA, LLC$163
  • Baxter Healthcare$158
  • Exact Sciences$70
  • plus $817 from 24 others

What the payments were for

  • Food & beverage$1,58980%
  • Other$39420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,984 in reported general payments places this provider in the 75th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$13,338
Medicare patients
159
Services billed
849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin64$58,191
EliquisApixaban48$45,275
OzempicSemaglutide33$43,190
FarxigaDapagliflozin Propanediol48$40,547
Tresiba Flextouch U-200Insulin Degludec15$36,320
Tresiba Flextouch U-100Insulin Degludec45$34,316
TrulicityDulaglutide19$24,983
JanuviaSitagliptin Phosphate20$15,685
MyrbetriqMirabegron17$13,785
LinzessLinaclotide15$12,235
Atrovent HfaIpratropium Bromide18$10,438
Janumet XrSitagliptin Phos/Metformin Hcl13$8,466
Lantus SolostarInsulin Glargine,hum.Rec.Anlog65$8,365
Levemir FlexpenInsulin Detemir23$5,822
Novolog FlexpenInsulin Aspart21$4,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$59$58,19164 claims
PfizerEliquis$68$45,27548 claims
Novo NordiskOzempic$292$43,19033 claims
AstraZenecaFarxiga$247$40,54748 claims
Lilly USA, LLCTrulicity$163$24,98319 claims
Astellas Pharma US IncMyrbetriq$14$13,78517 claims
AbbVieLinzess$44$12,23515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,706 family providers in Tennessee.

Other family in Paris

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →